Phenotypes Associated with This Genotype

Genotype
MGI:5771812

• Allelic Composition: Slc1a2^tm1.1Pros/Slc1a2^tm1.1Pros; Tg(GFAP-cre/ERT2)13Kdmc/0
• Genetic Background: involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:221590 )

• following postnatal tamoxifen treatment (P5-P9), mice die significantly earlier than control mice, with a median survival at 23 weeks of age

growth/size/body

slow postnatal weight gain ( J:221590 )

• tamoxifen-treated mice gain significantly less weight than controls from 10 weeks of age

behavior/neurological

behavior/neurological phenotype ( J:221590 )

N • at 28-67 weeks of age, tamoxifen-treated mice show no significant differences in total SHIRPA scores relative to control mice

seizures ( J:221590 )

• tamoxifen-treated mice show more electroencephalographic seizure events than controls

• however, no spontaneous clinical seizures are observed

nervous system

nervous system phenotype ( J:221590 )

N • at 14-19 weeks of age, tamoxifen-treated mice show only a minor, insignificant decrease in the uptake of L-[3H]glutamate (~15%) and D-[3H]aspartate (~13%) into crude forebrain synaptosomes relative to controls

seizures ( J:221590 )

• tamoxifen-treated mice show more electroencephalographic seizure events than controls

• however, no spontaneous clinical seizures are observed

abnormal brain wave pattern ( J:221590 )

• tamoxifen-treated mice show a significantly higher number of automatically detected spike-trains (electroencephalographic seizures) per 20 min of scalp EEG recording relative to controls (18.7 +/- 7.2 vs 1.9 +/- 0.5)